Clinical Trial

Cannabidiol in Sickle Cell Disease

Name: Cannabidiol in Sickle Cell Disease — clinical trial record (NCT06930703)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: SPICE

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

Randomized, placebo-controlled, double masked, dose finding study of twice daily cannabidiol given at 3 dose levels, 200mg, 400mg, and 600mg, compared to placebo for 4 weeks.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-04-09.

Status change: Not Yet Recruiting → Recruiting 2025-06-24

Trial Details

NCT Number	NCT06930703
Lead Sponsor	Icahn School of Medicine at Mount Sinai
Conditions	Sickle Cell Disease
Enrollment	52 participants
Start Date	2025-04-03
Primary Completion	2027-02-01 (estimated)
Study Completion	2027-02-01 (estimated)
Updated on ClinicalTrials.gov	2025-06-25